References
- 1 Anon .Fachinformation Elmendos 20 g/50 mg/100 mg/200 mg. In: GlaxoSmithKline ed.,
Rote Liste Service GmbH, Fachinfo - Service. 2006
- 2 Anon .Fachinformation Ergenyl Chrono 300 mg/500 mg. In: SanofiAventis ed.,
Rote Liste Service GmbH, Fachinfo - Service. 2006
- 3 Anon .Fachinformation Lamictal 2 mg/5 mg/25 mg/50 mg/100 mg/200 mg. In: GlaxoSmithKline
ed.,
Rote Liste Service GmbH, Fachinfo - Service. 2006
- 4
Baumann P, Hiemke C, Ulrich S. et al .
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry.
2004;
37
243-265
- 5
Bowden CL, Janicak PG, Orsulak P. et al .
Relation of serum valproate concentration to response in mania.
J Psychiatry.
1996;
153
765-770
- 6
Brodie MJ.
Lamotrigine.
Lancet.
1992;
339
1397-1400
- 7
Chan V, Morris RG, Ilett KF, Tett SE.
Population pharmacokinetics of lamotrigine.
Ther Drug Monit.
2001;
23
630-635
- 8
Devulder J.
The relevance of monitoring lamotrigine serum concentrations in chronic pain patients.
Acta neurol Belg.
2006;
106
15-18
- 9 Dickens M, Chen C. Lamotrigine: Chemistry, biotransformation and pharmacokinetics. In:
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds,
Antiepileptic Drugs. 5 edn. Philadelphia, Lippincott Williams & Wilkins 2002
- 10
Greiner C, Bader W, Haen E.
Drug monitoring of lamotrigine increases drug safety of concomitant use with valproate.
Drug Safety.
2006;
29
942
- 11
Greiner C, Haen E.
Development of a simple column-switching high performance-liquid chromatography (hplc)
method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine
and 10-hydroxycarbazepine (MHD).
J Chromatogr B;.
, in press
- 12
Greiner C, Haen E.
Therapeutic drug monitoring in psychiatry - reference ranges for the dose-concentration-relationship.
Psychiatrische Praxis.
2007;
34
90-92
- 13
Haen E.
Bedeutung der klinisch-pharmakologischen Befundung von Wirkstoffkonzentrationsmessungen
zur Therapieleitung.
Psychopharmakotherapie.
2005;
12
138-143
- 14
Haen E, Greiner C, Bader W, Wittmann M.
Wirkstoffkonzentrationsbestimmungen zur Therapieleitung - Ergänzung therapeutischer
Referenzbereiche durch dosisbezogene Referenzbereiche.
2007;
, , submitted to Nervenarzt
- 15
Kanner AM, Frey M.
Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.
Neurology.
2000;
55
588-591
- 16
Mataringa M-I, May TW, Rambeck B.
Does lamotrigine influence valproate concentrations?.
Ther Drug Monit.
2002;
24
631-636
- 17
May TW, Rambeck B, Jurgens U.
Serum concentrations of lamotrigine in epileptic patients: the influence of dose and
comedication.
Ther Drug Monit.
1996;
18
523-531
- 18
Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC.
Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction
of a routine service.
Brit J Clin Pharmacol.
1998;
46
547-551
- 19
Sbei M, Campellone JV.
Stupor from lamotrigine toxicity.
Epilepsia.
2001;
42
1082-1083
- 20
Walden J, Hesslinger B, Calker D Van, Berger M.
Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar
affective disorder.
Pharmacopsychiatry.
1996;
29
193-195
Correspondence
C. Greiner
Clinical Pharmacology
Department of Psychiatry, Psychosomatics and Psychotherapy
University of Regensburg
Universitaetsstrasse 84
93053 Regensburg
Germany
Phone: +49/941/941 20 74
Fax: +49/941/941 20 65
Email: christine.greiner@klinik.uni-regensburg.de
